Evidence map›Paper›PMID 25688241›Full record

ReviewFrontiers in immunology2014

γδ T Cells in HIV Disease: Past, Present, and Future.

C David Pauza, Bhawna Poonia, Haishan Li, Cristiana Cairo, Suchita Chaudhry

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. γδ T cells: origin and fate, subsets, diseases and immunotherapy.Signal transduction and targeted therapy · 2023
    Review
  14. Article
  15. Intestinal Microbiota Dysbiosis Promotes Mucosal Barrier Damage and Immune Injury in HIV-Infected Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

C David PauzaInstitute of Human Virology and Department of Medicine, University of Maryland School of Medicine , Baltimore, MD , USA.
Bhawna PooniaInstitute of Human Virology and Department of Medicine, University of Maryland School of Medicine , Baltimore, MD , USA.
Haishan LiInstitute of Human Virology and Department of Medicine, University of Maryland School of Medicine , Baltimore, MD , USA.
Cristiana CairoInstitute of Human Virology and Department of Medicine, University of Maryland School of Medicine , Baltimore, MD , USA.
Suchita ChaudhryInstitute of Human Virology and Department of Medicine, University of Maryland School of Medicine , Baltimore, MD , USA.
University of Maryland, Baltimore · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
FcRn-targeted mucosal HIV vaccineR01AI102680 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SALVATO, MARIA S., ZHU, XIAOPING · 2012 to 2015
$3.0M
Mechanisms for depleting tumor immunity in AIDSR01CA142458 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI PAUZA, C. DAVID · 2009 to 2012
$1.6M
Antigen exposure in utero: impacts on newborn immunity and infectious diseasesR01AI104702 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CAIRO, CRISTIANA · 2013 to 2016
$1.5M
T-follicular helper cells in Env-immunized macaquesR21AI096949 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAUZA, C. DAVID · 2012 to 2013
$411k
Genetic Polymorphisms in Rhesus Macaque FcRn and Association with IgG LevelsR03AI110229 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI POONIA, BHAWNA · 2014 to 2015
$154k
NCI NIH HHS R01 CA142458NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI102680NIAID NIH HHS R01 AI104702NIAID NIH HHS R03 AI110229NIAID NIH HHS R21 AI096949
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) type 1 dysregulates γδ T cells as part of an immune evasion mechanism. Nearly three decades of research defined the effects of HIV on γδ T cells and how this impacts disease. With highly effective antiretroviral therapy providing virus suppression and longer survival, we expected a return to normal for γδ T cells. This is not the case. Even in patients with CD4 T cell reconstitution, normal γδ T cell levels and function are not recovered. The durable damage to Vδ2 T cells is paralleled by defects in NK, CD8 T cells, and dendritic cells. Whether these consequences of HIV stem from similar or distinct mechanisms are not known and effective means for recovering the full range of cellular immunity have not been discovered. These unanswered questions receive too little attention in the overall program of efforts to cure HIV this disease. Approved drugs capable of increasing Vδ2 T cell function are being tested in clinical trials for cancer and hold promise for restoring normal function in patients with HIV disease. The impetus for conducting clinical trials will come from understanding the significance of γδ T cells in HIV disease and what might be gained from targeted immunotherapy. This review traces the history and current progress of AIDS-related research on γδ T cells. We emphasize the damage to γδ T cells that persists despite effective virus suppression. These chronic immune deficits may be linked to the comorbidities of AIDS (cancer, cardiovascular disease, metabolic disease, and others) and will hinder efforts to eradicate HIV by cytotoxic T or NK cell killing. Here, we focus on one subset of T cells that may be critical in the pathogenesis of HIV and an attractive target for new immune-based therapies.

Indexed as

gamma delta T cellHIVimmunotherapyVdelta1 gamma delta T cellsVgamma9Vdelta2 T cells

Identifiers

PMID25688241
PMCPMC4311680
OpenAlexW2077634460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.